News & Trends - MedTech & Diagnostics
Medtech company acquisition to fill obesity market gap
MedTech News: It is projected that by 2025 around 83% of Australian men and 75% of women aged 20 years and over will be overweight or obese, as well as one-third of 5-19 year olds. This equates to 16.9 million Australians.
Novo Nordisk has reported continued challenges in meeting demand for its obesity drug Wegovy and its diabetes medicine Ozempic, containing the same active ingredient semaglutide.
Boston Scientific’s move to acquire Apollo Endosurgery, for approximately $615 million, aims to fill the gap in the obesity market.
Boston Scientific is already among the leading companies within the endoscopic devices market for performing a variety of gastrointestinal surgeries, and Apollo Endosurgery also has a robust endoscopy product portfolio. Additionally, Apollo Endosurgery has historically been the leader of the gastric balloon market, as it has successfully marketed its Orbera System.
As Boston Scientific has yet to market bariatric devices, this acquisition will propel the company into the gastric balloons market which still play an important role in surgically treating obesity.
Analysts appeared upbeat about the acquisition as it will strengthen Boston Scientific’s GI portfolio, expand the company’s reach into an $800M endoluminal surgery market opportunity and the rapidly growing bariatric surgery segment.
Boston Scientific expects to complete the transaction in the first half of 2023.
In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - MedTech & Diagnostics
Government faces scrutiny for inaction in private hospital sector despite Health Check warnings
Shadow Health Minister Senator Anne Ruston questioned the Department of Health’s commitment to addressing critical issues in the private hospital […]
MoreNews & Trends - MedTech & Diagnostics
Australia lags behind in funding pharmacogenomic testing: Pathologists urge action
Diagnostics & MedTech News: The call for urgent action to improve access to pharmacogenomic testing across Australia comes as demand […]
MoreNews & Trends - Pharmaceuticals
Australia’s first Cholesterol Awareness Week launched to tackle nation’s ‘silent disease’
Pharma News: Leading heart charities have come together to launch the nation’s first Cholesterol Awareness Week (11-17 November), aiming to […]
More